Creat Group

The Creat Group is a Chinese investment firm based in Beijing incorporated in 1992.{{cite news|title=Introduction to Creat|url=http://www.creatgroup.com/?Enabout/about/id/1.html|accessdate=29 May 2017|publisher=Creat Group}} It has expertise in the plasma industry and invests in healthcare and pharmaceuticals, manufacturing, energy, finance, natural resources, and real estate.{{cite news |title=Creat Group |url=https://www.cbinsights.com/investor/creat-group |access-date=12 November 2022 |publisher=CB Insights}}

It bought Bio Products Laboratory from Bain Capital in May 2016 for £820 million.{{cite web|url=https://www.baincapital.com/news/creat-group-corporation-agrees-acquire-bio-products-laboratory-ltd | title=Creat Group Corporation agrees to acquire Bio Products Laboratory Ltd. | publisher=Bain Capital |date=18 May 2016 |accessdate=14 April 2017}} In 2017 it took over Biotest, the German blood plasma products maker.{{Cite news|url=https://www.reuters.com/article/us-biotest-m-a-creat-idUSKBN1791RC|title=Biotest agrees to takeover by China's Creat in 1.3 billion euro deal|date=2017-04-07|work=Reuters|access-date=2019-02-14|language=en}} It holds a stake in Shanghai RAAS Blood Products.{{cite news|title=China's Creat makes 1.2 billion euro bid for German blood plasma firm|url=https://www.reuters.com/article/us-biotest-m-a-creat-idUSKBN171104|accessdate=29 May 2017|publisher=Reuters|date=30 March 2017}}

The company obtains blood plasma from patients in the US and uses it to derive treatments in labs in Elstree.

Iain Duncan Smith referenced the company in 2020 when he complained about "the insertion of Chinese influence in all sorts of areas". BPL issued a statement saying “Since the acquisition, Creat has invested over £100 million in enhancing processes, talent and equipment to support the development of BPL Ltd into one of the world’s leading suppliers of plasma-derived therapies.”{{cite news |title=Iain Duncan Smith calls for review of Chinese investment in UK |url=https://www.theguardian.com/politics/2020/oct/11/iain-duncan-smith-calls-for-review-of-chinese-investment-in-uk-bpl-huawei |access-date=12 November 2022 |publisher=Guardian |date=11 October 2020}}